Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
This analysis examines publicly available formularies of plans available on the federally facilitated Affordable Care Act (ACA) Marketplace in 2024 to identify how utilization management tools are used for GLP-1 agonists
108 McLeanB
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ
Kailera IPO'd in 2025 with HRS9531 (dual GLP-1/GIP, Phase 3 China readout ~17.7% weight loss February 2026) as its lead asset and HRS-4729 (the triple agonist) as an earlier-stage follow-on
US$ 20.22
US$ 24.76
US$ 24.81
US$ 22.25
US$ 28.19
US$ 20.08
US$ 23.22
US$ 29.70
